Inhibrx Biosciences Inc.

INBX • Biotechnology

$121.17

▼ -1.09 (-0.89%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$1.90B

Growth

-8.3%

Cash Flow

0/5

Trend

Negative

Evidence

Healthy liquidity · 3.93High debt level · 13.39Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$121.17

Change-0.89%

Shares Out15.67M

Market Cap$1.90B

Enterprise Value$1.77B

52W Range22.40 - 155.29

Beta3.52

P/E-13.74

P/B-35.84

P/FCF-14.40

EV/EBITDA-14.23

EV/FCF-13.43

Price$121.17

Change-0.89%

Shares Out15.67M

Market Cap$1.90B

Enterprise Value$1.77B

52W Range22.40 - 155.29

Beta3.52

P/E-13.74

P/B-35.84

P/FCF-14.40

EV/EBITDA-14.23

EV/FCF-13.43

Earnings Yield-7.28%

FCF Yield-6.95%

Dividend Yield0.00%

Gross Margin-91.00%

Oper. Margin-103.87%

Profit Margin-107.73%

Debt/Eq13.39

Current Ratio3.93

Quick Ratio3.93

Revenue 5Y-8.26%

Target$285.00

Target Upside135.21%

Target Median$285.00

Target Range245.00 - 325.00

Volume251.19K

Avg Volume394.49K

EPS Surprise0.22

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

58/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

20/100

Why this score▼

Healthy liquidity · 3.93High debt level · 13.39Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

INBX

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

80/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$325.00

Mean

$325.00

Median

$325.00

High

$325.00

Company Overview

IPO: 5/29/2024

Industry: Biotechnology

P/B i: -35.84

Debt / Equity i: 13.39

Operating Margin: -10386.54%

Net Margin: -10773.46%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 13.39

Current Ratio: 3.93

Quick Ratio: 3.93

Status: Good

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

MANHARD KIMBERLY

Transaction: 06/03/2026

BUY

Change

+15,000

Price

$95.22

Filing

06/04/2026

Type

BUY

FORSYTH DOUGLAS

Transaction: 06/03/2026

BUY

Change

+15,000

Price

$95.22

Filing

06/04/2026

Type

BUY

Kayyem Jon Faiz

Transaction: 06/03/2026

BUY

Change

+15,000

Price

$95.22

Filing

06/04/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
MANHARD KIMBERLY	BUY	+15,000	$95.22	06/03/2026	06/04/2026
FORSYTH DOUGLAS	BUY	+15,000	$95.22	06/03/2026	06/04/2026
Kayyem Jon Faiz	BUY	+15,000	$95.22	06/03/2026	06/04/2026
Vuori Kristiina MD	BUY	+15,000	$95.22	06/03/2026	06/04/2026
Matly David	BUY	+50,000	$129.06	04/24/2026	04/27/2026
VIKING GLOBAL INVESTORS LP	SELL	-16,315	$32.25	10/07/2025	10/09/2025
FORSYTH DOUGLAS	BUY	+15,000	$12.91	05/28/2025	05/29/2025
Kayyem Jon Faiz	BUY	+15,000	$12.91	05/28/2025	05/29/2025
Vuori Kristiina MD	BUY	+15,000	$12.91	05/28/2025	05/29/2025
MANHARD KIMBERLY	BUY	+15,000	$12.91	05/28/2025	05/29/2025
Matly David	OTHER	+175,000	$15.86	04/01/2025	04/02/2025
Deck Kelly	BUY	+15,000	$14.05	04/01/2025	04/02/2025
Kayyem Jon Faiz	SELL	-90,000	Not reported	03/27/2025	03/28/2025
Kayyem Jon Faiz	BUY	+250,000	Not reported	12/16/2024	12/17/2024
Kayyem Jon Faiz	SELL	-52,000	Not reported	12/06/2024	12/06/2024
Kayyem Jon Faiz	BUY	+18,750	$14.19	11/20/2024	11/22/2024
Kayyem Jon Faiz	BUY	+34,843	$14.23	11/19/2024	11/22/2024
Vuori Kristiina MD	BUY	+6,667	$15.00	10/03/2024	10/07/2024
Lappe Mark	BUY	+13,037	$17.13	09/16/2024	09/16/2024
Lappe Mark	BUY	+26,963	$15.05	09/12/2024	09/16/2024

About the Company

Inhibrx Biosciences Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Source - link

Peers

AMLX ATAI CVAC ELVN IMTX NKTR ORIC RLAY SANA SNDX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.

PRNewsWire

Inhibrx Reports Second Quarter 2026 Financial Results

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

PRNewsWire

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.

Seeking Alpha

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the "Credit Facility"). The Second Amendment provides for an additional tranche, in an aggregate principal amount of up to $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the "Term C Loan") and (ii) up to an additional $225.0 million of which may be funded in increments of $50.0 million or more upon the Company's request and at the Lenders' sole discretion (the "Term D Loan").

PRNewsWire

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-2.37	-2.15	0.22
2026-03-19	-2.08	-2.11	-0.03
2025-11-14	-2.08	-2.28	-0.2
2025-08-13	-2.92	-1.85	1.07
2025-05-14	-2.55	-2.8	-0.25
2025-03-17	-2.88	-3.09	-0.21
2024-11-14	-3.06	-2.84	0.22
2024-08-13	-3.6	125.48	129.08
2024-06-03	-1.04	-1.44	-0.4
2024-02-28	-1.07	-1.73	-0.66
2023-11-09	-1.01	-1.1	-0.09
2023-08-07	-1.02	-1.08	-0.06